{"id":50775,"date":"2022-11-11T19:02:07","date_gmt":"2022-11-11T18:02:07","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/medable-named-a-leader-in-decentralized-clinical-trial-products-assessment-for-second-consecutive-year-by-everest-group\/"},"modified":"2022-11-11T19:02:07","modified_gmt":"2022-11-11T18:02:07","slug":"medable-named-a-leader-in-decentralized-clinical-trial-products-assessment-for-second-consecutive-year-by-everest-group","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/medable-named-a-leader-in-decentralized-clinical-trial-products-assessment-for-second-consecutive-year-by-everest-group\/","title":{"rendered":"Medable Named a Leader in Decentralized Clinical Trial Products Assessment for Second Consecutive Year by Everest Group"},"content":{"rendered":"
\n

PALO ALTO, Calif.–(BUSINESS WIRE)–#biotech<\/a>—Medable Inc.<\/a>, the industry-leading technology platform for patient-centered clinical trials, today announced that it was named a Leader in the \u201cDecentralized Clinical Trial Products PEAK Matrix\u00ae Assessment<\/a> 2022\u201d by Everest Group for the second consecutive year. The report evaluates decentralized clinical trial (DCT) products from 24 companies based on vision, capability and market impact. Medable rated highest in the Leaders quadrant with top scores for vision, capability and market impact.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nThis recognition underscores Medable\u2019s leadership in the industry shift to DCTs. Since 2020, Medable has deployed its software-as-a-service platform via more than 300 decentralized and hybrid clinical trials in 60 countries, serving more than one million people globally. By minimizing the need for in-person site visits, Medable customers have achieved unprecedented results \u2013 including 200 percent faster enrollment and 50 percent cost reductions. In fact, a new study<\/a> from Tufts Center for the Study of Drug Development shows that, on average, DCTs can achieve net financial benefits ranging from five to 13 times for Phase II and Phase III trials, equating to roughly $10 million ROI and $39 million ROI respectively.\n<\/p>\n

\n\u201cWe could not be prouder to be recognized as a Leader by Everest Group for the second year running,\u201d said Michelle Longmire, CEO and co-founder of Medable. \u201cThe future of clinical research will be defined by a patient-first approach to conducting trials \u2013 and Medable is poised to provide life sciences companies with a scalable, enterprise SaaS platform that unlocks the tools they need to be successful across their entire portfolio. We will continue leading the way toward making trials more accessible, effective, and representative of all populations to enable effective therapies to reach patients faster.\u201d\n<\/p>\n

\nEverest Group\u2019s PEAK Matrix\u00ae Assessment is based on two dimensions and multiple criteria:\n<\/p>\n